Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 224.63
KALV's Cash-to-Debt is ranked higher than
53% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. KALV: 224.63 )
Ranked among companies with meaningful Cash-to-Debt only.
KALV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 63.75 Max: No Debt
Current: 224.63
0.32
No Debt
Equity-to-Asset 0.46
KALV's Equity-to-Asset is ranked lower than
76% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. KALV: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
KALV' s Equity-to-Asset Range Over the Past 10 Years
Min: -6.65  Med: 0.87 Max: 0.95
Current: 0.46
-6.65
0.95
Debt-to-Equity 0.01
KALV's Debt-to-Equity is ranked higher than
94% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. KALV: 0.01 )
Ranked among companies with meaningful Debt-to-Equity only.
KALV' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.2  Med: 0.01 Max: 0.11
Current: 0.01
-0.2
0.11
Debt-to-EBITDA -0.01
KALV's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. KALV: -0.01 )
Ranked among companies with meaningful Debt-to-EBITDA only.
KALV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.53  Med: -0.56 Max: -0.01
Current: -0.01
-1.53
-0.01
Piotroski F-Score: 5
Altman Z-Score: 5.46
WACC vs ROIC
22.36%
142.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -168.62
KALV's Operating Margin % is ranked lower than
58% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. KALV: -168.62 )
Ranked among companies with meaningful Operating Margin % only.
KALV' s Operating Margin % Range Over the Past 10 Years
Min: -40265.52  Med: -711.72 Max: -119.18
Current: -168.62
-40265.52
-119.18
Net Margin % -132.38
KALV's Net Margin % is ranked lower than
55% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. KALV: -132.38 )
Ranked among companies with meaningful Net Margin % only.
KALV' s Net Margin % Range Over the Past 10 Years
Min: -46065.52  Med: -536.15 Max: -132.38
Current: -132.38
-46065.52
-132.38
ROE % -56.86
KALV's ROE % is ranked lower than
57% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. KALV: -56.86 )
Ranked among companies with meaningful ROE % only.
KALV' s ROE % Range Over the Past 10 Years
Min: -56.86  Med: -53.96 Max: -53.96
Current: -56.86
-56.86
-53.96
ROA % -31.66
KALV's ROA % is ranked higher than
50% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. KALV: -31.66 )
Ranked among companies with meaningful ROA % only.
KALV' s ROA % Range Over the Past 10 Years
Min: -217.52  Med: -62.96 Max: -24.07
Current: -31.66
-217.52
-24.07
ROC (Joel Greenblatt) % -1670.60
KALV's ROC (Joel Greenblatt) % is ranked lower than
70% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. KALV: -1670.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KALV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -41029.73  Med: -8987.78 Max: -1670.6
Current: -1670.6
-41029.73
-1670.6
3-Year Revenue Growth Rate -50.90
KALV's 3-Year Revenue Growth Rate is ranked lower than
83% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. KALV: -50.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
KALV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -50.9  Med: 66.35 Max: 128.9
Current: -50.9
-50.9
128.9
3-Year EBITDA Growth Rate 61.20
KALV's 3-Year EBITDA Growth Rate is ranked higher than
96% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. KALV: 61.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
KALV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -132.8  Med: -13.85 Max: 61.2
Current: 61.2
-132.8
61.2
3-Year EPS without NRI Growth Rate 64.80
KALV's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. KALV: 64.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
KALV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.2 Max: 64.8
Current: 64.8
0
64.8
GuruFocus has detected 3 Warning Signs with KalVista Pharmaceuticals Inc KALV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KALV's 30-Y Financials

Financials (Next Earnings Date: 2019-03-16 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

KALV Guru Trades in Q4 2017

Jim Simons 88,728 sh (New)
» More
Q1 2018

KALV Guru Trades in Q1 2018

Jim Simons 43,428 sh (-51.05%)
» More
Q2 2018

KALV Guru Trades in Q2 2018

Jim Simons 35,728 sh (-17.73%)
» More
Q3 2018

KALV Guru Trades in Q3 2018

Jim Simons 117,349 sh (+228.45%)
» More
» Details

Insider Trades

Latest Guru Trades with KALV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

KalVista Pharmaceuticals Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325411    SIC: 2834
Compare:TPE:1733, XPAR:GNRO, OTCPK:NWBO, OSL:TRVX, NAS:OPHT, OSTO:MVIR B, ASX:MDC, TSX:APS, NAS:LPTX, NAS:KRYS, NAS:EIGR, XMCE:ORY, OTCPK:CYDY, FRA:PB9, NAS:BLRX, ROCO:4193, TSE:4572, LSE:DDDD, ROCO:4726, OSTO:IBT B » details
Traded in other countries:4XC1.Germany,
Headquarter Location:USA
KalVista Pharmaceuticals Inc is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases.

KalVista Pharmaceuticals Inc is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates through the region of United States.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 31.48
KALV's Price-to-Owner-Earnings is ranked higher than
79% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. KALV: 31.48 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
KALV' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.97  Med: 10.62 Max: 34.47
Current: 31.48
7.97
34.47
PB Ratio 9.05
KALV's PB Ratio is ranked lower than
55% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. KALV: 9.05 )
Ranked among companies with meaningful PB Ratio only.
KALV' s PB Ratio Range Over the Past 10 Years
Min: 0.29  Med: 2.64 Max: 9.9
Current: 9.05
0.29
9.9
PS Ratio 19.62
KALV's PS Ratio is ranked lower than
57% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. KALV: 19.62 )
Ranked among companies with meaningful PS Ratio only.
KALV' s PS Ratio Range Over the Past 10 Years
Min: 3.68  Med: 23.08 Max: 8213.33
Current: 19.62
3.68
8213.33
Price-to-Free-Cash-Flow 37.38
KALV's Price-to-Free-Cash-Flow is ranked higher than
76% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. KALV: 37.38 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
KALV' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.42  Med: 12.53 Max: 40.92
Current: 37.38
8.42
40.92
Price-to-Operating-Cash-Flow 28.76
KALV's Price-to-Operating-Cash-Flow is ranked higher than
79% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. KALV: 28.76 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
KALV' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.17  Med: 10.62 Max: 31.49
Current: 28.76
8.17
31.49
EV-to-EBIT -16.27
KALV's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. KALV: -16.27 )
Ranked among companies with meaningful EV-to-EBIT only.
KALV' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.74  Med: -2.1 Max: 1.8
Current: -16.27
-16.74
1.8
EV-to-EBITDA -16.44
KALV's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. KALV: -16.44 )
Ranked among companies with meaningful EV-to-EBITDA only.
KALV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.91  Med: -2.1 Max: 1.8
Current: -16.44
-16.91
1.8
EV-to-Revenue 27.45
KALV's EV-to-Revenue is ranked higher than
52% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. KALV: 27.45 )
Ranked among companies with meaningful EV-to-Revenue only.
KALV' s EV-to-Revenue Range Over the Past 10 Years
Min: -1587.8  Med: 16 Max: 6283
Current: 27.45
-1587.8
6283
Current Ratio 2.41
KALV's Current Ratio is ranked lower than
68% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. KALV: 2.41 )
Ranked among companies with meaningful Current Ratio only.
KALV' s Current Ratio Range Over the Past 10 Years
Min: 0.39  Med: 7.87 Max: 19.68
Current: 2.41
0.39
19.68
Quick Ratio 2.41
KALV's Quick Ratio is ranked lower than
65% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. KALV: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
KALV' s Quick Ratio Range Over the Past 10 Years
Min: 0.39  Med: 7.87 Max: 19.68
Current: 2.41
0.39
19.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -84.10
KALV's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. KALV: -84.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KALV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -107.4  Med: -60.75 Max: -33.6
Current: -84.1
-107.4
-33.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 14.95
KALV's Price-to-Net-Cash is ranked lower than
54% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. KALV: 14.95 )
Ranked among companies with meaningful Price-to-Net-Cash only.
KALV' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.36  Med: 2.6 Max: 15.32
Current: 14.95
0.36
15.32
Price-to-Net-Current-Asset-Value 10.48
KALV's Price-to-Net-Current-Asset-Value is ranked higher than
60% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. KALV: 10.48 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KALV' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.36  Med: 2.33 Max: 10.75
Current: 10.48
0.36
10.75
Price-to-Tangible-Book 9.53
KALV's Price-to-Tangible-Book is ranked higher than
53% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. KALV: 9.53 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KALV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.36  Med: 2.32 Max: 9.77
Current: 9.53
0.36
9.77
Price-to-Median-PS-Value 0.90
KALV's Price-to-Median-PS-Value is ranked higher than
73% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. KALV: 0.90 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
KALV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 1.29 Max: 286
Current: 0.9
0.17
286
Earnings Yield (Greenblatt) % -6.13
KALV's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. KALV: -6.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KALV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -407.8  Med: -40.5 Max: 3981.3
Current: -6.13
-407.8
3981.3

More Statistics

Revenue (TTM) (Mil) $12.02
EPS (TTM) $ -1.50
Beta3.25
Volatility92.90%
52-Week Range $7.73 - 25.57
Shares Outstanding (Mil)17.18

Analyst Estimate

Apr19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -1.69
EPS without NRI ($) -1.69
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}